OKYO PHARMA LTD Stock Price, News & Analysis

OKYO Pharma (NASDAQ: OKYO) announced on Dec 15, 2025 that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 24,551 ordinary shares on NASDAQ.

After the purchase, the Chairman's total holding increased to 10,516,297 shares. OKYO is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition currently without an FDA-approved therapy.

OKYO Pharma (NASDAQ: OKYO) reported new analyses from its placebo-controlled, randomized, double-masked Phase 2 trial of 0.05% urcosimod in neuropathic corneal pain (NCP) on Dec 11, 2025. The 18-patient trial's exploratory corneal nerve imaging (in vivo confocal microscopy) showed median increases for 0.05% patients in total nerve fiber count (+2.0 n/0.16 mm², IQR 0.54–3.63) and total nerve fiber length (+2.6 mm/mm², IQR 1.55–5.67; p = 0.057 vs placebo).

The placebo group showed median decreases in nerve count (–1.92 n/0.16 mm², IQR –2.79 to –0.04) and length (–1.63 mm/mm², IQR –3.76 to 0.63). Results are described as exploratory (n = 4 per reported median) and presented as directionally favorable for corneal nerve structure, supporting further investigation.

OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 27,051 ordinary shares on NASDAQ on Dec 3, 2025.

The purchase increases the Chairman's total holding to 10,491,746 shares. The company is developing urcosimod for neuropathic corneal pain, a condition with no FDA-approved therapy.

OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 82,018 ordinary shares on NASDAQ on November 21, 2025.

The purchase increases the Chairman's total holding to 10,464,695 shares. The company is developing urcosimod for neuropathic corneal pain (NCP), an ocular condition without an FDA-approved therapy.

OKYO Pharma (NASDAQ: OKYO) announced that CEO Gary S. Jacob, Ph.D. will present at OIS XV in San Diego on November 22, 2025 from 8:30–9:30 AM PT during the Anterior Innovation Showcase. The presentation will highlight OKYO's lead investigational drug urcosimod, a lipidated peptide for neuropathic corneal pain (NCP).

OKYO said recent positive top-line Phase 2 results support advancing to a 120-patient multi-center clinical trial, and the OIS XV session aims to engage clinicians, partners, and investors to accelerate development.

OKYO Pharma (NASDAQ: OKYO) will present at the 33rd Annual BIO-Europe partnering conference in Vienna on November 3-5, 2025. CEO Gary S. Jacob, Ph.D., will highlight OKYO's lead investigational candidate, urcosimod, and provide updates from the company's recently completed Phase 2 clinical trial for neuropathic corneal pain (NCP).

The management team will hold one-on-one partnering meetings to discuss clinical milestones, recent positive clinical data for urcosimod, and plans to accelerate its clinical development program for ocular inflammatory diseases.

OKYO Pharma (NASDAQ: OKYO) announced on October 16, 2025 that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 ordinary shares on NASDAQ. The purchase increases the chairman's total holding to 10,382,677 shares. The company is developing urcosimod for neuropathic corneal pain, a condition currently without an FDA-approved therapy.

OKYO Pharma (NASDAQ: OKYO) has announced plans for an expanded clinical trial of urcosimod, its lead drug candidate for treating neuropathic corneal pain (NCP). Following successful Phase 2 results where 75% of patients showed over 80% pain reduction, the company will conduct a 100-patient multi-center clinical trial across multiple U.S. sites.

The new multiple-ascending-dose (MAD) trial aims to identify optimal dosing for Phase 3 trials and further understand urcosimod's micellar characteristics. The company expects topline data in 2026. With Fast-Track designation from the FDA, OKYO is preparing for regulatory discussions to define primary endpoints for potential registration.

OKYO Pharma (NASDAQ: OKYO) has secured $1.9 million in non-dilutive funding to accelerate the development of urcosimod, its lead drug candidate for treating Neuropathic Corneal Pain (NCP). The funding will support ongoing R&D programs and advance clinical milestones without impacting existing shareholder equity.

NCP is a severely debilitating ocular condition characterized by chronic nerve-related pain that currently has no FDA-approved treatments. The company will use the funds to advance clinical development, expand R&D efforts, and progress urcosimod's regulatory pathway, demonstrating its commitment to fiscal responsibility while developing innovative therapies.